• Evaluating Tissue Marking Dyes for Small Biopsy Integrity in

  2026-06-19

  This article examines a recent study assessing the effectiveness of various tissue marking dyes, including alcian blue and hematoxylin, for enhancing the visibility and retention of small tissue biopsies during pathology processing. The findings indicate that hematoxylin offers a favorable balance of visibility and diagnostic compatibility, with implications for improving histological workflow and sample integrity.

• EPZ5676: Advanced DOT1L Inhibitor Workflows in Leukemia Rese

  2026-06-19

  EPZ5676 enables precision targeting of H3K79 methylation in MLL-rearranged leukemia models, delivering nanomolar potency and exceptional selectivity. This guide distills applied protocols, troubleshooting, and recent translational insights to maximize data quality and reproducibility.

• Lypressin Acetate: Applied Workflows for Vasopressin Researc

  2026-06-18

  Lypressin acetate empowers translational research in vasopressin receptor biology, diabetes insipidus modeling, and emerging antiviral assays. This guide delivers actionable protocol enhancements, troubleshooting strategies, and data-driven comparisons—enabling reproducible, high-impact results.

• Fasudil (HA-1077) HCl: Optimizing ROCK Inhibitor Application

  2026-06-18

  Fasudil (HA-1077) HCl, a benchmark ROCK inhibitor from APExBIO, empowers researchers to dissect Rho/ROCK pathway roles in cancer, cell motility, and hematological models with reproducible precision. This guide delivers actionable workflow enhancements, protocol optimizations, and troubleshooting insights tailored to advanced cellular and in vivo studies.

• Masitinib (AB1010): Technical Guidance for KIT/PDGFR Inhibit

  2026-06-17

  Masitinib (AB1010) addresses the need for selective inhibition of KIT and PDGFR kinases in studies of cancer biology, mastocytosis, and inflammatory disease. This compound is best deployed in DMSO-based workflows requiring precise kinase targeting, and is not appropriate for protocols demanding broad-spectrum inhibition or aqueous/ethanol solubility.

• CLCC1 Identified as Essential for Herpesvirus Nuclear Egress

  2026-06-17

  A recent study establishes the host chloride channel CLCC1 as a critical mediator of membrane fusion during herpesvirus nuclear egress. This finding elucidates a previously uncharacterized step in viral replication, with implications for nuclear envelope morphogenesis and the development of targeted antiviral strategies.

• Perphenazine: Dopamine D2 Antagonist for Neuropharmacology &

  2026-06-16

  Perphenazine’s multi-receptor antagonism equips researchers for both neuropharmacology and innovative host-directed antibacterial strategies. This guide delivers protocol-ready insights, troubleshooting, and the latest workflow advances for leveraging this compound in cell death, schizophrenia, and immune modulation assays.

• Masitinib (AB1010): Technical Guidance for KIT/PDGFR Inhibit

  2026-06-16

  Masitinib (AB1010) is a potent, selective tyrosine kinase inhibitor tailored for research targeting KIT, PDGFRα, and PDGFRβ signaling. It is best deployed in DMSO-based protocols requiring precise kinase inhibition in cancer biology, mastocytosis, or inflammatory disease studies, but is not suitable for workflows dependent on aqueous or ethanol solubility, or broad-spectrum kinase inhibition.

• EPZ5676: DOT1L Inhibitor Advancing MLL Leukemia Research

  2026-06-15

  EPZ5676, a next-generation DOT1L inhibitor, transforms experimental workflows for MLL-rearranged leukemia by delivering unparalleled selectivity and robust efficacy in both in vitro and in vivo settings. Its nanomolar potency and high selectivity enable precise H3K79 methylation inhibition, making it an indispensable tool for mechanistic and translational epigenetic research.

• Modeling Malignant Mesothelioma in Genetically Engineered Mi

  2026-06-15

  Kadariya et al. present a comprehensive framework for modeling malignant mesothelioma using genetically engineered mouse models (GEMMs) that closely replicate key genetic and immunological features of human disease. Their protocols enable precise investigation of gene-environment interactions and preclinical therapeutic assessment, advancing the translational relevance of mouse models in mesothelioma research.

• Applied Workflows with Alcian Blue & Nuclear Fast Red Staini

  2026-06-14

  The Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5, streamlines the detection of acid mucopolysaccharides and chondrogenic differentiation, eliminating pre-incubation and enhancing contrast for precise tissue analysis. Discover how this APExBIO solution optimizes workflow, improves reproducibility, and supports advanced histology research.

• Verteporfin (CL 318952): Super-Enhancer Modulation in Ocular

  2026-06-13

  Explore the multifaceted role of Verteporfin in ocular neovascularization and stem cell differentiation. This in-depth analysis integrates new insights into super-enhancer regulation, positioning Verteporfin as an advanced tool for photodynamic therapy and regenerative research.

• EPZ5676: Redefining DOT1L Inhibition for Precision Epigeneti

  2026-06-12

  Explore how EPZ5676, a potent DOT1L inhibitor, empowers advanced epigenetic studies with unmatched selectivity and practical insight into H3K79 methylation inhibition. This article reveals new experimental strategies and assay guidance not found in other reviews.

• Enhancing Cell Viability Assays with Cell Counting Kit-8 (CC

  2026-06-12

  This article offers a scenario-driven, evidence-based guide for deploying Cell Counting Kit-8 (CCK-8) (SKU K1018) in cell viability, proliferation, and cytotoxicity assays. It addresses common laboratory challenges, provides protocol insights, and benchmarks APExBIO's CCK-8 for reliability and workflow efficiency.

• Masitinib (AB1010): Technical Guidance for KIT/PDGFR Assays

  2026-06-11

  Masitinib (AB1010) is a selective phenylaminothiazole-type tyrosine kinase inhibitor optimized for research targeting KIT, PDGFRα, and PDGFRβ signaling. It is best suited for DMSO-based protocols in cancer, mastocytosis, and inflammatory disease models, but is not appropriate for workflows requiring aqueous or ethanol solubility, or broad-spectrum kinase inhibition.

16246 records 1/1084 page Next 12345 下5页 Last page